A live-attenuated vaccine currently in development has demonstrated safety and 100% efficacy against the Lassa virus in preclinical studies. Researchers from the Texas Biomedical Research Institute (Texas Biomed), The Scripps Research Institute, and the National Institute of Allergy and Infectious Diseases (NIAID) have developed a vaccine candidate for Lassa virus that successfully protected guinea pigs …